Annually, around 2.9 million cholera cases and 95,000 deaths in 69 endemic countries are estimated in the updated global burden of cholera in 2015. Often, cholera remains under-reported in some settings due to limited surveillance capability and accessibility/utilization of healthcare service, etc. At times, cholera outbreaks have been reported vaguely as “acute watery diarrhea” because of economic and social concerns and the stigma attached to cholera as a “disease of the poor.” Currently, Ethiopia is actively responding and fighting cholera to eradicate the disease. IVI’s ECCP project was launched in 2021 with support from LG Electronics, the Korea Support Committee (KSC) for IVI and other Korean donors and is striving to fight cholera through large-scale vaccination campaigns and disease surveillance activities.
The ECCP project aims to provide free vaccinations to around 100,000 residents including children (above one year of age) living in cholera-vulnerable areas and also establish a disease surveillance system to strengthen local public health capabilities. IVI is working closely with the Ethiopian government-affiliated organizations Armauer Hansen Research Institute (AHRI) under the umbrella of the Ethiopian Ministry of Health (MoH), which also includes Ethiopian Public Health Institute (EPHI), Ethiopian Pharmaceuticals Supply Agency (EPSA), and government health bureaus of Oromia Region and Shashemene.